The path to the standardization of PTH: Is this a realistic possibility? a position paper of the IFCC C-BM.

[en] Parathyroid hormone (PTH) determination is of greatest importance for patients suffering from parathyroid gland disorders and for the follow-up of bone turnover in patients suffering from chronic kidney disease (CKD). Two generations of PTH assays are simultaneously present on the market for PTH quantification. As these assays are not yet standardized, this results in a significant level of confusion in the care of CKD patients. One key objective of the IFCC Committee for Bone Metabolism is to improve this situation. In this position paper, we will highlight the current state of PTH testing and propose a pathway to ultimately overcome issues resulting from PTH assay variability.

Disciplines :

Laboratory medicine & medical technology

Author, co-author :

Cavalier, Etienne ; Université de Liège - ULiège > Département de pharmacie > Chimie médicale

Vasikaran, Samuel

Bhattoa, Harjit P.

Heijboer, Annemieke C.

Makris, Konstantinos

Ulmer, Candice Z.

Language :

English

Title :

The path to the standardization of PTH: Is this a realistic possibility? a position paper of the IFCC C-BM.

Publication date :

January 2021

Journal title :

Clinica Chimica Acta

ISSN :

0009-8981

eISSN :

1873-3492

Publisher :

Elsevier, Netherlands

Volume :

515

Pages :

44-51

Peer reviewed :

Peer Reviewed verified by ORBi

Commentary :

Available on ORBi :

since 26 February 2021

Statistics

Number of views

47 (4 by ULiège)

Number of downloads

4 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Friedman, P.A., Molecular biology of parathyroid hormone. Textb Nephro-Endocrinol. 1 (2009), 95–104, 10.1016/B978-0-12-373870-7.00008-9.
Pfister, M.F., Ruf, I., Stange, G., Ziegler, U., Lederer, E., Biber, J., et al. Parathyroid hormone leads to the lysosomal degradation of the renal type II Na/Pi cotransporter. Proc. Natl. Acad. Sci. 95 (1998), 1909–1914, 10.1073/pnas.95.4.1909.
Fermor, B., Skerry, T.M., PTH/PTHrP receptor expression on osteoblasts and osteocytes but not resorbing bone surfaces in growing rats. J. Bone Miner. Res. 10 (2009), 1935–1943, 10.1002/jbmr.5650101213.
Yavropoulou, M.P., Michopoulos, A., Yovos, J.G., PTH and PTHR1 in osteocytes. New insights into old partners. Hormones 16 (2017), 150–160.
Gardella, T.J., Axelrod, D., Rubin, D., Keutmann, H.T., Potts, J.T., Kronenberg, H.M., et al. Mutational analysis of the receptor-activating region of human parathyroid hormone. J. Biol. Chem. 266 (1991), 13141–13146.
Segre, G.V., Perkins, A.S., Witters, L., Potts, J.T., Metabolism of parathyroid hormone by isolated Rat Kupffer cells and hepatocytes. J. Clin. Invest. 67 (1981), 449–457.
Hanley, D.A., Ayer, L.M., Calcium-dependent release of carboxyl-terminal fragments of parathyroid hormone byhyperplastic human parathyroid tissue in vitro. J. Clin. Endocrinol. Metab. 63 (1986), 1075–1079, 10.1210/jcem-63-5-1075.
Mayer, G.P., Keaton, J.A., Hurst, J.G., Habener, J.F., Effects of plasma calcium concentration on the relative proportion of hormone and carboxyl fragments in parathyroid venous blood. Endocrinology 104 (1979), 1778–1784, 10.1210/endo-104-6-1778.
Yamashita, H., Gao, P., Cantor, T., Futata, T., Murakami, T., Uchino, S., et al. Large carboxy-terminal parathyroid hormone (PTH) fragment with a relatively longer half-life than 1–84 PTH is secreted directly from the parathyroid gland in humans. Eur. J. Endocrinol. 149 (2003), 301–306, 10.1530/eje.0.1490301.
Yamashita, H., Cantor, T., Uchino, S., Watanabe, S., Ogawa, T., Moriyama, T., et al. Sequential changes in plasma intact and whole parathyroid hormone levels during parathyroidectomy for secondary hyperparathyroidism. World J. Surg. 29 (2005), 169–173, 10.1007/s00268-004-7489-y.
D'amour, P., Lazure, C., Labelle, F., Metabolism of radioiodinated carboxy-terminal fragments of bovine parathyroid hormone in normal and anephric rats*. Endocrinology 117 (1985), 127–134, 10.1210/endo-117-1-127.
D'Amour, P., Circulating PTH molecular forms: what we know and what we don't. Kidney Int. 70 (2006), S29–S33, 10.1038/sj.ki.5001599.
Costa, A.G., Cremers, S., Dworakowski, E., Lazaretti-Castro, M., Bilezikian, J.P., Comparison of two commercially available ELISAs for circulating sclerostin. Osteoporos. Int. 25 (2014), 1547–1554, 10.1007/s00198-014-2635-3.
KDIGO 2017, Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int. Suppl. 7 (2017) 1–59.
London, G.M., Marchais, S.J., Guérin, A.P., Boutouyrie, P., Métivier, F., De Vernejoul, M.C., Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J. Am. Soc. Nephrol. 19 (2008), 1827–1835, 10.1681/ASN.2007050622.
Soliman, M., Hassan, W., Yaseen, M., Rao, M., Sawaya, B.P., El-Husseini, A., PTH assays in dialysis patients: practical considerations. Semin. Dial., 2018, 1–6, 10.1111/sdi.12743.
Lamina, C., Kronenberg, F., Stenvinkel, P., Froissart, M., Forer, L., Schönherr, S., et al. Association of changes in bone mineral parameters with mortality in haemodialysis patients: Insights from the ARO cohort. Nephrol. Dial. Transplant. 35 (2020), 478–487, 10.1093/ndt/gfz060.
Cavalier, E., Plebani, M., Delanaye, P., Souberbielle, J.-C., Considerations in parathyroid hormone testing. Clin. Chem. Lab. Med., 2015, 10.1515/cclm-2015-0314.
Cavalier, E., Delanaye, P., Vranken, L., Bekaert, A.-C., Carlisi, A., Chapelle, J.-P., et al. Interpretation of serum PTH concentrations with different kits in dialysis patients according to the KDIGO guidelines: importance of the reference (normal) values. Nephrol. Dial. Transplant. 27 (2011), 1950–1956, 10.1093/ndt/gfr535.
Deckers, M.M.L., de Jongh, R.T., Lips, P.T.A.M., Penninx, B.W.J.H., Milaneschi, Y., Smit, J.H., et al. Prevalence of vitamin D deficiency and consequences for PTH reference values. Clin. Chim. Acta 426 (2013), 41–45, 10.1016/j.cca.2013.08.024.
Berson, S.A., Yalow, R.S., Aurbach, G.D., Potts, J.T., Immunoassay of bovine and human parathyroid hormone. Proc. Natl. Acad. Sci. 49 (1963), 613–617.
Nussbaum, S.R., Zahradnik, R.J., Lavigne, J.R., Brennan, G.L., Nozawa-Ung, K., Kim, L.Y., et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin. Chem. 33 (1987), 1364–1367.
Lepage, R., Roy, L., Brossard, J.H., Rousseau, L., Dorais, C., Lazure, C., et al. A non-(1–84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin. Chem. 44 (1998), 805–809.
Quarles, L.D., Lobaugh, B., Murphy, G., Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J. Clin. Endocrinol. Metab. 75 (1992), 145–150, 10.1210/jcem.75.1.1619003.
Wang, M., Hercz, G., Sherrard, D.J., Maloney, N.A., Segre, G.V., Pei, Y., Relationship between intact 1–84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am. J. Kidney Dis. 26 (1995), 836–844, 10.1016/0272-6386(95)90453-0.
John, M.R., Goodman, W.G., Ping, G., Cantor, T., Salusky, I.B., Juppner, H., A novel Immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J. Clin. Endocrinol. Metab. 84 (1999), 4287–4290.
Gao, P., Scheibel, S., D'Amour, P., John, M.R., Rao, S.D., Schmidt-Gayk, H., et al. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1–84: implications for improvement of accurate assessment of parathyroid function. J. Bone Miner. Res. 16 (2001), 605–614, 10.1359/jbmr.2001.16.4.605.
D'Amour, P., Brossard, J.H., Rousseau, L., Roy, L., Gao, P., Cantor, T., Amino-Terminal Form of Parathyroid Hormone (PTH) with Immunologic Similarities to hPTH(1–84) Is Overproduced in Primary and Secondary Hyperparathyroidism. Clin. Chem. 49 (2003), 2037–2044, 10.1373/clinchem.2003.021592.
Cavalier, E., Daly, A.F., Betea, D., Pruteanu-Apetrii, P.N., Delanaye, P., Stubbs, P., et al. The ratio of parathyroid hormone as measured by third- and second-generation assays as a marker for parathyroid carcinoma. J. Clin. Endocrinol. Metab. 95 (2010), 3745–3749, 10.1210/jc.2009-2791.
Cavalier, E., Betea, D., Schleck, M.L., Gadisseur, R., Vroonen, L., Delanaye, P., et al. The third/second generation PTH assay ratio as a marker for parathyroid carcinoma: Evaluation using an automated platform. J. Clin. Endocrinol. Metab. 99 (2014), 453–457, 10.1210/jc.2013-3730.
Arakawa, T., D'Amour, P., Rousseau, L., Brossard, J.H., Sakai, M., Kasumoto, H., et al. Overproduction and secretion of a novel amino-terminal form of parathyroid hormone from a severe type of parathyroid hyperplasia in uremia. Clin. J. Am. Soc. Nephrol. 1 (2006), 525–531, 10.2215/CJN.01391005.
Sturgeon, C.M., Sprague, S., Almond, A., Cavalier, E., Fraser, W.D., Algeciras-Schimnich, A., et al. Perspective and priorities for improvement of parathyroid hormone (PTH) measurement – a view from the IFCC Working Group for PTH. Clin. Chim Acta 467 (2017), 42–47, 10.1016/j.cca.2016.10.016.
Miller, W.G., Myers, G.L., Commutability still matters. Clin. Chem. 59 (2013), 1291–1293, 10.1373/clinchem.2013.208785.
Phinney, K.W., Sempos, C.T., Tai, S.S.-C., Camara, J., Wise, S., Eckfeldt, J.H., et al. Baseline assessment of 25-Hydroxyvitamin D reference material and proficiency testing/external quality assurance material commutability: a vitamin D standardization program study. J. AOAC Int. 100 (2017), 1–6, 10.5740/jaoacint.17-0291.
Hocher, B., Zeng, S., Clear the fog around parathyroid hormone assays. Clin. J. Am. Soc. Nephrol. 13 (2018), 1–3, 10.2215/CJN.01730218.
Ursem, S.R., Vervloet, M.G., Hillebrand, J.J.G., De Jongh, R.T., Heijboer, A.C., Oxidation of PTH: in vivo feature or effect of preanalytical conditions?. Clin. Chem. Lab. Med. 56 (2018), 249–255, 10.1515/cclm-2017-0313.
Ursem, S.R., Vervloet, M.G., de Jongh, R.T., Heijboer, A.C., Oxidation of parathyroid hormone. Clin. Chim Acta 506 (2020), 84–91, 10.1016/j.cca.2020.03.020.
Souberbielle, J.-C., Brazier, F., Piketty, M.-L., Cormier, C., Minisola, S., Cavalier, E., How the reference values for serum parathyroid hormone concentration are (or should be) established?. J. Endocrinol. Invest., 40, 2017, 10.1007/s40618-016-0553-2.
Souberbielle, J.-C., Boutten, A., Carlier, M.-C., Chevenne, D., Coumaros, G., Lawson-Body, E., et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int. 70 (2006), 345–350, 10.1038/sj.ki.5001606.
Singh, R.J., Hines, J.M., Lopez, M.F., Krastins, B., Hoofnagle, A.N., Mass spectrometric immunoassay raises doubt for the existence of parathyroid hormone fragment 7–84. Clin. Chem. 61 (2015), 558–560, 10.1373/clinchem.2014.235440.
Cantor, T., Yang, Z., Caraiani, N., Ilamathi, E., Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: implication for treatment decisions. Clin. Chem. 52 (2006), 1771–1776, 10.1373/clinchem.2006.071589.
Cavalier, E., Delanaye, P., Krzesinski, J.M., Chapelle, J.P., Comparison of Liaison N-tact PTH (Diasorin) and N-tact PTH SP IRMA (Diasorin) in hemodialyzed patients. Clin. Chem. Lab. Med. 43 (2005), 890–891, 10.1515/CCLM.2005.151.
Hecking, M., Kainz, A., Bielesz, B., Plischke, M., Beilhack, G., Hörl, W.H., et al. Clinical evaluation of two novel biointact PTH(1–84) assays in hemodialysis patients. Clin. Biochem. 45 (2012), 1645–1651, 10.1016/j.clinbiochem.2012.08.006.
Almond, A., Ellis, A.R., Walker, S.W., Current parathyroid hormone immunoassays do not adequately meet the needs of patients with chronic kidney disease. Ann. Clin. Biochem. 49 (2012), 63–67, 10.1258/acb.2011.011094.
Eddington, H., Hudson, J.E., Oliver, R.L., Fraser, W.D., Hutchison, A.J., Kalra, P.A., Variability in parathyroid hormone assays confounds clinical practice in chronic kidney disease patients. Ann. Clin. Biochem. 51 (2014), 228–236, 10.1177/0004563213491236.
Einbinder, Y., Benchetrit, S., Golan, E., Zitman-Gal, T., Comparison of intact PTH and bio-intact PTH assays among non-dialysis dependent chronic kidney disease patients. Ann. Lab. Med. 37 (2017), 381–387, 10.3343/alm.2017.37.5.381.
Dupuy, A.M., Bargnoux, A.S., Morena, M., Lauret, E., Souberbielle, J.C., Cavalier, E., et al. Moving from the second to the third generation Roche PTH assays: what are the consequences for clinical practice ?. Clin. Chem. Lab. Med., 2018.
O'Flaherty, D., Sankaralingam, A., Scully, P., Manghat, P., Goldsmith, D., Hampson, G., The relationship between intact PTH and biointact PTH (1–84) with bone and mineral metabolism in pre-dialysis chronic kidney disease (CKD). Clin. Biochem. 46 (2013), 1405–1409, 10.1016/j.clinbiochem.2013.06.023.
Monge, M., Jean, G., Bacri, J.L., Lemaitre, V., Masy, E., Joly, D., et al. Higher parathyroid hormone (PTH) concentrations with the Architect PTH assay than with the Elecsys assay in hemodialysis patients, and a simple way to standardize these two methods. Clin. Chem. Lab. Med. 47 (2009), 362–366, 10.1515/CCLM.2009.068.
Kakuta, T., Ishida, M., Fukagawa, M., Critical governance issue of parathyroid hormone assays and its selection in the management of chronic kidney disease mineral and bone disorders. Ther. Apher. Dial. 22 (2018), 220–228, 10.1111/1744-9987.12690.
Tan, K., Ong, L., Sethi, S.K., Saw, S., Comparison of the Elecsys PTH(1–84) assay with four contemporary second generation intact PTH assays and association with other biomarkers in chronic kidney disease patients. Clin. Biochem. 46 (2013), 781–786, 10.1016/j.clinbiochem.2013.01.016.
Cavalier, E., Delanaye, P., Lukas, P., Carlisi, A., Gadisseur, R., Souberbielle, J.-C., Standardization of DiaSorin and Roche automated third generation PTH assays with an International Standard: impact on clinical populations. Clin. Chem. Lab. Med. 52 (2014), 7–11, 10.1515/cclm-2013-1027.
Cavalier, E., Salsé, M., Dupuy, A.-M., Bargnoux, A.-S., Watar, F., Souberbielle, J.-C., et al. Establishment of reference values in a healthy population and interpretation of serum PTH concentrations in hemodialyzed patients according to the KDIGO Guidelines using the Lumipulse® G whole PTH (3rd generation) assay. Clin. Biochem., 2018, 119–122, 10.1016/j.clinbiochem.2018.02.019 Apr.
Gannagé-Yared, M.H., Farès, C., Ibrahim, T., Rahal, Z.A., Elias, M., Chelala, D., Comparison between a second and a third generation parathyroid hormone assay in hemodialysis patients. Metabolism 62 (2013), 1416–1422, 10.1016/j.metabol.2013.05.007.
Gardien, P., Moineau, M.P., Kerspern, H., Bordron, A., Carre, J.L., Comparative study of parathormone and vitamin D measurements by three automats: ADVIA Centaur XP ® (Siemens), ISYS® (IDS) and Liaison® (Diasorin). Ann. Biol. Clin. (Paris) 72 (2014), 543–548, 10.1684/abc.2014.0973.
La'ulu, S.L., Roberts, W.L., Performance characteristics of six intact parathyroid hormone assays. Am. J. Clin. Pathol. 134 (2010), 930–938, 10.1309/AJCPLGCZR7IPVHA7.
Koivula, M.K., Laitinen, P., Risteli, J., Evaluation of IDS-ISYS intact parathyroid hormone (iPTH) and comparison to siemens advia centaur® iPTH assay in chronic renal failure patients and in controls. Clin. Lab. 58 (2012), 403–410.
Fernández-Galán, E., Bedini, J.L., Filella, X., Analytical verification and method comparison of the ADVIA Centaur® intact parathyroid hormone assay. Clin. Biochem. 50 (2017), 1222–1227, 10.1016/j.clinbiochem.2017.09.006.
Taniguchi, M., Tanaka, M., Hamano, T., Nakanishi, S., Fujii, H., Kato, H., et al. Comparison between whole and intact parathyroid hormone assays. Ther. Apher. Dial. 15 (2011), 42–49, 10.1111/j.1744-9987.2011.00926.x.
Sheth, R.D., Stuart, S.L., Comparison of 1–84 and intact parathyroid hormone assay in pediatric dialysis patients. Pediatr. Nephrol. 20 (2005), 977–981, 10.1007/s00467-005-1862-4.
Kato, Y., Yamaguchi, S., Yachiku, S., Fujisawa, M., Kawakami, N., Efficacy of whole PTH assay and 1–84/NON-(1–84) PTH ratio in patients on hemodialysis or undergoing parathyroidectomy. Acta Urol. Jpn. 50 (2004), 755–762.
Donati, G., Cianciolo, G., Capelli, I., Baraldi, O., Gambaretto, C., Demelas, V., et al. Comparison of two parathyroid hormone assays in hemodialysis patients. Artif. Organs 40 (2016), 1013–1016, 10.1111/aor.12661.